Literature DB >> 9860402

Corticosteroid therapy augments gastroduodenal permeability to sucrose.

S Kiziltaş1, N Imeryüz, T Gürcan, A Siva, S Saip, A Dumankar, C Kalayci, N B Ulusoy.   

Abstract

OBJECTIVE: The aim of the present study was to investigate whether corticosteroid therapy alters gastroduodenal mucosal permeability and whether permeability alteration is associated with macroscopic mucosal damage.
METHODS: Eight patients taking oral corticosteroid therapy (total prednisone-equivalent dose, 1.5+/-0.1 g; duration, approximately 30 days), nine patients with multiple sclerosis taking high-dose intravenous methyl-prednisolone therapy (total dose, 11.7+/-0.5 g; duration, approximately 9 days), and 20 age- and gender-matched controls were studied. Gastroduodenal permeability was determined using sucrose as a site-specific permeability probe. Five-hour urine was collected after ingesting 100 g of sucrose and its urinary excretion rate was measured using high-pressure liquid chromatography. Gastroduodenal endoscopy was performed before steroid therapy to exclude subjects with evidence of macroscopic mucosal lesions. The sucrose test and endoscopy were repeated after completion of corticosteroid therapy.
RESULTS: The urinary sucrose excretion rates were similar in the control group and in patient groups before corticosteroid therapy. The median excretion rate of sucrose increased four (one to 28)- and eight (two to 35)-fold, respectively, as compared with pretreatment values in patients taking oral steroid and high-dose intravenous methyl-prednisolone therapy (p < 0.01). Considering all patients together, subjects who received a mean prednisone-equivalent dose of 8.4+/-1.5 g exhibited mucosal lesions, whereas patients who received 3.3+/-1.8 g did not (p = 0.06). The post-therapy increments in sucrose excretion rates were associated with neither the presence of macroscopic lesions nor with the total steroid dose received.
CONCLUSIONS: Corticosteroid therapy augments gastroduodenal permeability and high doses are associated with macroscopic mucosal lesions. Steroid-induced permeability increase does not appear to be associated with the presence of macroscopic mucosal lesions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9860402     DOI: 10.1111/j.1572-0241.1998.00697.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  8 in total

1.  Behçet's Disease.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-09       Impact factor: 3.598

2.  Significance of a novel sucrose permeability test using serum in the diagnosis of early gastric cancer.

Authors:  Tadayuki Shishido; Taketo Yamaguchi; Takeo Odaka; Masanori Seimiya; Hiromitsu Saisho; Fumio Nomura
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

3.  Behçet's Disease.

Authors:  Gulsen Akman-Demir; Sabahattin Saip; Aksel Siva
Journal:  Curr Treat Options Neurol       Date:  2011-06       Impact factor: 3.598

4.  Effects of aspirin on gastroduodenal permeability in alcoholics and controls.

Authors:  Ashkan Farhadi; Ali Keshavarzian; Mary J Kwasny; Maliha Shaikh; Louis Fogg; Cynthia Lau; Jeremy Z Fields; Christopher B Forsyth
Journal:  Alcohol       Date:  2010-07-03       Impact factor: 2.405

5.  Increased sucrose permeability in Behçet's disease.

Authors:  Bayram Koc; Serdar Aymelek; Alper Sonmez; M Ilker Yilmaz; Hakki Kocar
Journal:  Rheumatol Int       Date:  2003-10-07       Impact factor: 2.631

6.  Alkaline Phosphatase Activity and Endotoxemia After Infant Cardiothoracic Surgery.

Authors:  Jesse A Davidson; Tracy T Urban; Suhong Tong; Aline Maddux; Gerald Hill; Benjamin S Frank; John D Watson; James Jaggers; Eric A F Simões; Paul Wischmeyer
Journal:  Shock       Date:  2019-03       Impact factor: 3.454

7.  Primary Peritonitis Secondary to Streptococcus pyogenes in a Young Female Adult-A Case Report and Literature Review.

Authors:  Avelyn E Y Aw; James W K Lee; Kon Voi Tay
Journal:  Infect Dis Rep       Date:  2021-01-01

8.  KIR4.1 Antibodies as Biomarkers in Multiple Sclerosis.

Authors:  Marie Wunsch; Damiano M Rovituso; Stefanie Kuerten
Journal:  Front Neurol       Date:  2014-04-30       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.